A numbers-first look at Torrent Pharmaceuticals Ltd. (TORNTPHARM), covering income trends, margins, valuation, and shareholding.
Torrent Pharma Revenue Trend
Revenue advanced 20.3% to ₹13,886 Cr in FY2026, a solid print that reflects broad-based demand momentum for Torrent Pharmaceuticals Ltd.
The 10-year revenue CAGR of 7.6% captures steady top-line expansion from ₹6,676 Cr to ₹13,886 Cr, not explosive but consistent through multiple market cycles.
At ₹13,886 Cr in annual revenue, Torrent Pharmaceuticals Ltd. holds a meaningful position among Indian pharmaceuticals companies by scale.
Year-on-year data shows Torrent Pharmaceuticals Ltd. has strung together 9 consecutive years of revenue growth, a track record that speaks to operational durability.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹13,886 Cr | +20.3% |
| FY2025 | ₹11,539 Cr | +7.0% |
| FY2024 | ₹10,786 Cr | +11.6% |
| FY2023 | ₹9,665 Cr | +11.0% |
| FY2022 | ₹8,705 Cr | — |
View Torrent Pharmaceuticals Ltd.'s full 10-year revenue trend with CAGR analysis →
Torrent Pharma Profitability
Net profit rose 11.9% to ₹2,138 Cr in FY2026, a healthy gain even if the pace trailed the top-line growth.
Net margin eased to 15.4% in FY2026 from 16.6% the year before, suggesting cost pressure or mix shift partially offset the revenue gain.
Diluted EPS came in at ₹63.92 in FY2026, up from ₹56.47 in FY2025, marking the per-share earnings improvement.
Is Torrent Pharma Undervalued
Applying the P/E Ratio methodology, the calculated intrinsic value works out to ₹4,037.
Torrent Pharmaceuticals Ltd. shares are currently trading at ₹4,514.10.
Craytheon also values the business using EPS Growth and DCF models, with full assumptions laid out in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹4,037 | 10.6% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Torrent Pharmaceuticals Ltd. with detailed assumptions →
Torrent Pharma Shareholding Pattern
Promoters hold 68.3% of the company, a stake that has remained unchanged over recent quarters.
Foreign institutional investors held 16.2% as of March 2026, nudging up from 16.1% in the prior period.
The DII stake stood at 9.1% as of March 2026, compared to 8.7% in the year-ago period, indicating measured domestic institutional accumulation.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 68.3% | 16.2% | 9.1% | 6.5% |
| Dec 2025 | 68.3% | 16.1% | 9.1% | 6.4% |
| Sep 2025 | 68.3% | 15.9% | 9.3% | 6.5% |
| Jun 2025 | 68.3% | 16.1% | 8.7% | 6.9% |
Track quarterly shareholding changes for Torrent Pharmaceuticals Ltd. →
Torrent Pharma Balance Sheet
Proportional view as of 23 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2026 total assets: ₹443.13B (up 195.6% YoY from ₹149.90B).
Top categories: Intangibles & Goodwill (63.8%), Property, Plant & Equipment (10.6%), Inventories (7.1%).
Of the ₹443.12B in liabilities and equity, 39.7% is shareholder equity, 33.9% is interest-bearing debt, and 26.4% is operating liabilities. Over the year, debt is up 369.2% and equity is up 131.7%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 19.83B |
| Receivables | 30.31B |
| Inventories | 31.38B |
| Property, Plant & Equipment | 47.04B |
| Investments | 826.20M |
| Intangibles & Goodwill | 282.70B |
| Other Assets | 31.05B |
| Category | Value |
|---|---|
| Equity | 175.85B |
| Short-term Debt | 31.84B |
| Long-term Debt | 118.41B |
| Trade Payables | 23.58B |
| Other Liabilities | 93.44B |
Torrent Pharma — The Bottom Line
Putting it together, Torrent Pharmaceuticals Ltd.'s financials offer a reasonably clear picture for investors sizing up this pharmaceuticals stock.
Revenue reached ₹13,886 Cr in FY2026, growing 20.3% year-over-year.
Over 10 years, the top line has compounded at 7.6% annually.
The business is profitable, posting a net margin of 15.4% on net income of ₹2,138 Cr.
The P/E Ratio model implies 10.6% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Torrent Pharmaceuticals Ltd..